On June 10th, researchers from Eli Lilly published findings of a randomized phase 2a clinical trial in "Nature Medicine" titled Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. The study indicated that Retatrutide (LY3437943), a GLP-1R-related triple receptor agonist currently under clinical development, demonstrated significant efficacy and favorable safety in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD)
Glutathione, pronounced (gloota-thigh-own), is a molecule produced by your body that acts as a critical antioxidant, ridding your body of free radicals
Does ILU Collective ship GLP-1 medication
Bypass = GLP-1 + GIP Interestingly, GIP is greatly reduced because food completely skips the place that produces it
Next-generation multimodal agonists combine GLP-1 activity with other incretin or metabolic targets
Have you ever wondered if the supplements you take could be influencing your weight